Divya Ratan Verma, MD
Cardiovascular Disease · Murray, UTNPI 1710181318
Payments from drug & device makers
Across 529 payments — averaging $2153.35 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$984K
- Abbott$64K
- Janssen Research & Development, LLC$30K
- Boston Scientific$29K
- Abiomed$23K
- Medical Device Business Services, Inc.$2K
- plus $9K from 25 others
What the payments were for
- Speaking & faculty fees$12,25026%
- Travel & lodging$12,26926%
- Food & beverage$22,78348%
- Education$550%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic(2 entities) | 154 | $984,054 |
| Abbott | 96 | $63,761 |
| Janssen Research & Development, LLC | 3 | $29,565 |
| Boston Scientific | 82 | $28,586 |
| Abiomed | 68 | $22,643 |
| Medical Device Business Services, Inc. | 5 | $1,942 |
| Siemens Medical Solutions USA, Inc. | 8 | $1,872 |
| Edwards Lifesciences | 18 | $1,531 |
| Philips North America LLC | 4 | $1,107 |
| Boehringer Ingelheim | 13 | $536 |
| Cvrx, Inc. | 9 | $487 |
| Shockwave Medical, Inc | 6 | $479 |
| Penumbra, Inc. | 5 | $424 |
| Amgen | 11 | $369 |
| Cardiovascular Systems Inc. | 5 | $294 |
| E.r. Squibb & Sons, L.L.C. | 3 | $206 |
| Johnson & Johnson(2 entities) | 4 | $184 |
| Heartflow, Inc. | 2 | $168 |
| Novartis | 6 | $155 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 10 | $154 |
| AstraZeneca | 1 | $119 |
| Cardiva Medical, Inc. | 4 | $101 |
| Endotronix, Inc. | 1 | $97 |
| Livanova USA, Inc. | 2 | $89 |
| Impulse Dynamics (USA) Inc. | 2 | $44 |
| Angiodynamics, Inc. | 1 | $42 |
| Lexicon Pharmaceuticals, Inc. | 2 | $29 |
| Astellas Pharma US Inc | 1 | $25 |
| Kiniksa Pharmaceuticals International, PLC | 1 | $24 |
| Asahi Intecc USA, Inc. | 1 | $21 |
| Pfizer | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Impella$21,066
- COREVALVE EVOLUT R$4,108
- Carto 3 System$1,835
- TRICLIP$1,218
- Edwards SAPIEN 3 Ultra Transcatheter Heart Valve$948
- Intracardiac Undivided$890
- MitraClip$596
- CoreValve Evolut$472
- ONYX FRONTIER$463
- RESOLUTE ONYX$404
- MitraClip System$386
- Diamondback Coronary$384
- Mitra Clip system$340
- JARDIANCE$340
- WATCHMAN Access System$321
- SAPIEN 3 Ultra RESILIA$300
- 3F$273
- Watchman$267
- Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter$207
- Barostim Neo System$164
How this compares
$1,139,124 in reported general payments places this provider in the 95th percentile of 131 cardiovascular disease providers in Utah.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| CamzyosMavacamten | 42 | $344,543 |
| JardianceEmpagliflozin | 126 | $153,578 |
| EliquisApixaban | 30 | $34,214 |
| EntrestoSacubitril/Valsartan | 30 | $31,328 |
| BrilintaTicagrelor | 34 | $29,903 |
| Metoprolol Succinate | 61 | $836 |
| Nitroglycerin | 24 | $494 |
| ClopidogrelClopidogrel Bisulfate | 43 | $437 |
| Atorvastatin Calcium | 43 | $397 |
| Furosemide | 49 | $270 |
| Isosorbide Mononitrate ErIsosorbide Mononitrate | 24 | $206 |
| Carvedilol | 67 | $204 |
| Rosuvastatin Calcium | 18 | $154 |
| Spironolactone | 25 | $104 |
| Losartan Potassium | 18 | $92 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| E.r. Squibb & Sons, L.L.C.Camzyos | $206 | $344,54342 claims |
| Boehringer IngelheimJardiance | $536 | $153,578126 claims |
| PfizerEliquis | $14 | $34,21430 claims |
| NovartisEntresto | $155 | $31,32830 claims |
| AstraZenecaBrilinta | $119 | $29,90334 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 131 cardiovascular disease providers in Utah.
Other cardiovascular disease in Murray
- Brian WhisenantMurray$3.4M
- Kia AfsharMurray$442K
- Rami AlharethiMurray$403K
- Joseph MuhlesteinMurray$308K
- James OrfordMurray$98K
- Stephen MillerMurray$95K
- Kirk KnowltonMurray$53K
- Travis MossMurray$6K
- Jonathan HarrisonMurray$5K
- Alpana SenapatiMurray$4K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.